Abstract #4243

Spectroscopic Imaging-based detection of 2-hydroxyglutarate (2HG) in IDH1 mutant human gliomas on 3T Clinical

Gaurav Verma¹, Sanjeev Chawla¹, Harish Poptani², MacLean Nasrallah³, Michael Albert Thomas⁴, Arati Desai⁵, Steven Brem⁶, and Suyash Mohan⁷

¹Neuroradiology, University of Pennsylvania, Philadelphia, PA, United States, ²Cellular and Molecular Physiology, University of Liverpool, Liverpool, United Kingdom, ³Pathology, University of Pennsylvania, Philadelphia, PA, United States, ⁴Radiology, University of California Los Angeles, Los Angeles, CA, United States, ⁵Hematology Oncology, University of Pennsylvania, Philadelphia, PA, United States, ⁶Neurosurgical Oncology, University of Pennsylvania, Philadelphia, PA, United States, ⁷Radiology, University of Pennsylvania, Philadelphia, PA, United States

Mutations in isocitrate dehydrogenase (IDH) play an increasing role in clinical assessment of human gliomas and determination of treatment. The performance of Chemical Shift Imaging (CSI) to detect 2-hydroxyglutarate (2HG) in mutant-IDH gliomas was assessed in the routine clinical environment. Specificity of 80% and sensitivity of 63% was achieved in a cohort of 15 patients scanned with the technique at 3T. Greater sensitivity, through longer acqusition or more sensitive equipment could result in reliable non-invasive detection of this putative biomarker present in a majority of Grade II/III gliomas.

This abstract and the presentation materials are available to members only; a login is required.

Join Here